Literature DB >> 33470330

Value of left atrial diameter with CHA2DS2-VASc score in predicting left atrial/left atrial appendage thrombosis in non-valvular atrial fibrillation.

Yu Zhang1, Yi-Qiang Yuan1.   

Abstract

BACKGROUND: Atrial fibrillation is the most common persistent arrhythmia, and is the main factor that leads to thromboembolism.
OBJECTIVE: To investigate the value of left atrial diameter combined with CHA2DS2-VASc score in predicting left atrial/left atrial appendage thrombosis in non-valvular atrial fibrillation.
METHODS: This is a retrospective study. 238 patients with non-valvular atrial fibrillation were selected and divided into two groups: thrombosis and non-thrombosis. CHA2DS2-VASc score was determined. P<0.05 was considered statistically significant.
RESULTS: Multivariate logistic regression analysis revealed that the history of stroke/transient ischemic attack, vascular disease, CHA2DS2-VASc score, left atrial diameter (LAD), left ventricular end-diastolic dimension (LVEDD) and left ventricular ejection fraction (LVEF) were independent risk factors for left atrial/left atrial appendage thrombosis (p<0.05). Receiver operating characteristic curve analysis revealed that the area under the curve for the CHA2DS2-VASc score in predicting left atrial/left atrial appendage thrombosis was 0.593 when the CHA2DS2-VASc score was ≥3 points, and sensitivity and specificity were 86.5% and 32.6%, respectively, while the area under the curve for LAD in predicting left atrial/left atrial appendage thrombosis was 0.786 when LAD was ≥44.17 mm, and sensitivity and specificity were 89.6% and 60.9%, respectively. Among the different CHA2DS2-VASc groups, the incidence rate of left atrial/left atrial appendage thrombosis in patients with LAD ≥44.17 mm was higher than patients with LAD <44.17 mm (p<0.05).
CONCLUSION: CHA2DS2-VASc score and LAD are correlated with left atrial/left atrial appendage thrombosis in non-valvular atrial fibrillation. For patients with a CHA2DS2-VASc score of 0 or 1, when LAD is ≥44.17 mm, the risk for left atrial/left atrial appendage thrombosis remained high. (Arq Bras Cardiol. 2020; [online].ahead print, PP.0-0).

Entities:  

Year:  2021        PMID: 33470330      PMCID: PMC7909979          DOI: 10.36660/abc.20190492

Source DB:  PubMed          Journal:  Arq Bras Cardiol        ISSN: 0066-782X            Impact factor:   2.000


  14 in total

Review 1.  Meta-analysis of CHADS2 versus CHA2DS2-VASc for predicting stroke and thromboembolism in atrial fibrillation patients independent of anticoagulation.

Authors:  Wen-Gen Zhu; Qin-Mei Xiong; Kui Hong
Journal:  Tex Heart Inst J       Date:  2015-02-01

2.  Incidence and Predictors of Left Atrial Appendage Thrombus in Patients Treated With Nonvitamin K Oral Anticoagulants Versus Warfarin Before Catheter Ablation for Atrial Fibrillation.

Authors:  Joanne Wyrembak; Kristen B Campbell; Benjamin A Steinberg; Tristram D Bahnson; James P Daubert; Eric J Velazquez; Zainab Samad; Brett D Atwater
Journal:  Am J Cardiol       Date:  2017-01-05       Impact factor: 2.778

Review 3.  Anticoagulation Bridge Therapy in Patients with Atrial Fibrillation: Recent Updates Providing a Rebalance of Risk and Benefit.

Authors:  Candice L Garwood; Bianca Korkis; Domenico Grande; Claudia Hanni; Amy Morin; Lynette R Moser
Journal:  Pharmacotherapy       Date:  2017-06-06       Impact factor: 4.705

Review 4.  Effectiveness and Safety of Non-vitamin K Antagonist Oral Anticoagulants for Atrial Fibrillation and Venous Thromboembolism: A Systematic Review and Meta-analyses.

Authors:  Abdulaali R Almutairi; Lili Zhou; Walid F Gellad; Jeannie K Lee; Marion K Slack; Jennifer R Martin; Wei-Hsuan Lo-Ciganic
Journal:  Clin Ther       Date:  2017-06-28       Impact factor: 3.393

Review 5.  Warfarin and the Risk of Stroke and Bleeding in Patients With Atrial Fibrillation Receiving Dialysis: A Systematic Review and Meta-analysis.

Authors:  Ziv Harel; Glenn M Chertow; Prakesh S Shah; Shai Harel; Paul Dorian; Andrew T Yan; Gustavo Saposnik; Manish M Sood; Amber O Molnar; Jeffrey Perl; Rachel M Wald; Sam Silver; Ron Wald
Journal:  Can J Cardiol       Date:  2017-02-20       Impact factor: 5.223

Review 6.  Left Atrial Appendage Occlusion for Stroke Prevention.

Authors:  Arijit Chanda; John P Reilly
Journal:  Prog Cardiovasc Dis       Date:  2017-04-28       Impact factor: 8.194

7.  Left ventricular mass predicts left atrial appendage thrombus in persistent atrial fibrillation.

Authors:  Anita C Boyd; Tanya McKay; Siroos Nasibi; David A B Richards; Liza Thomas
Journal:  Eur Heart J Cardiovasc Imaging       Date:  2012-07-24       Impact factor: 6.875

8.  Impact of Diastolic Function Parameters on the Risk for Left Atrial Appendage Thrombus in Patients with Nonvalvular Atrial Fibrillation: A Prospective Study.

Authors:  Rami Doukky; Enrique Garcia-Sayan; Mita Patel; Rojina Pant; Marwan Wassouf; Saurabh Shah; Oliver D'Silva; Richard F Kehoe
Journal:  J Am Soc Echocardiogr       Date:  2016-03-25       Impact factor: 5.251

9.  Effect of Metabolic Syndrome on Risk Stratification for Left Atrial or Left Atrial Appendage Thrombus Formation in Patients with Nonvalvular Atrial Fibrillation.

Authors:  Yu-Yang Chen; Qi Liu; Li Liu; Xiao-Rong Shu; Zi-Zhuo Su; Hai-Feng Zhang; Ru-Qiong Nie; Jing-Feng Wang; Shuang-Lun Xie
Journal:  Chin Med J (Engl)       Date:  2016-10-20       Impact factor: 2.628

10.  Left atrial appendage volume increased in more than half of patients with cryptogenic stroke.

Authors:  Mikko Taina; Ritva Vanninen; Marja Hedman; Pekka Jäkälä; Satu Kärkkäinen; Tero Tapiola; Petri Sipola
Journal:  PLoS One       Date:  2013-11-04       Impact factor: 3.240

View more
  2 in total

1.  Predicting Values of Neutrophil-to-Lymphocyte Ratio (NLR), High-Sensitivity C-Reactive Protein (hs-CRP), and Left Atrial Diameter (LAD) in Patients with Nonvalvular Atrial Fibrillation Recurrence After Radiofrequency Ablation.

Authors:  Bing Ding; Pengfei Liu; Fangfang Zhang; Jie Hui; Linyan He
Journal:  Med Sci Monit       Date:  2022-01-27

2.  Tackling Bleeding - One Appendage at a Time.

Authors:  Stefano Garzon; Willterson Carlos Bandeira
Journal:  Arq Bras Cardiol       Date:  2022-07       Impact factor: 2.667

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.